Wells Fargo assumed coverage of Alaunos Therapeutics with an Overweight rating and $3 price target, with no changes made to rating or target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TCRT: